Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Reata Pharmaceuticals Q1 Earnings
Reata Pharmaceuticals (NASDAQ:RETA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
Reata Pharmaceuticals Earnings Preview
Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Reata... 
Via Benzinga
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
One analyst says Reata only has a 50% chance in a neurodegenerative disease. 
Via Investor's Business Daily
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 38.3% to $1.66 during Monday's regular session. The current volume of 3.5 million shares is 142.9% of TC... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022
Upgrades For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1.... 
Via Benzinga
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
Reata Pharmaceuticals's Return on Invested Capital Insights
Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon'... 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack... 
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
Recap: Reata Pharmaceuticals Q4 Earnings
Reata Pharmaceuticals (NASDAQ:RETA) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
FDA Strikes Off Reata Pharma's Bardoxolone Application For Rare Kidney Disease
The FDA has issued a Complete Response Letter (CRL) regarding Reata Pharmaceuticals Inc's (NASDAQ: RETA) application seeking approval for bardoxolone... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Final Deadline Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.